ClinicalTrials.gg
TerminatedNCT01673490FDC114785Updated Aug 20, 2018Results posted

Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia

A Phase 4 interventional study of Dutasteride/Tamsulosin in Prostatic Hyperplasia, sponsored by GlaxoSmithKline. Terminated at 1 site in Vietnam. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2018-08-20.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Why this study was terminated
The sole investigative site refused to accept the amended protocol and declined to continue the study. There was no safety signal nor any other reason.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing dutasteride in Prostatic Hyperplasia — 1 open to participants now, 1 under way, none of them phase 3. Dutasteride · Prostatic Hyperplasia.

Enrollment
9th of 27
59 · median 44
Started
2012
with 1 other
Phase 4
10 of 27
1 open now
Registered
21st of 27
by date
Lead sponsor
15 of 27
GlaxoSmithKline

Among the 27 studies testing dutasteride in Prostatic Hyperplasia, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 4, and was the 21st registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

1 of the 27 studies testing dutasteride in Prostatic Hyperplasia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dutasteride

Dutasteride: first FDA approval 2001 (AVODART). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing dutasteride in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

Open-label, 6 month-treatment with the IP in all subjects. - Sample size: A total of 90 subjects will be enrolled so that among them at least 57 will complete the 6-month treatment period and evaluable for analysis.

-Primary objective: To assess the safety of 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy for six month in BPH patients by monitoring category, frequency and severity of adverse events encountered during the treatment period.

-Secondary objective: To assess the efficacy of 0.5 mg dutasteride/0.4 mg tamsulosin combination therapy with regard to symptom improvement in BPH patients by monitoring and analyzing of changes in IPSS and Qmax after 6 months of treatment.

Read the detailed description

Visit 0 or Screening Visit (M0) - D0 + 2): Following tasks will be performed: ICF collection, subject code assignment, physical examination (vital signs, demographic data, medical history); checking of inclusion and exclusion criteria: prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, total PSA level, free-to-total PSA ratio, Qmax, urinalysis, transrectal prostate ultrasonography (TRUS), 12-lead electrocardiography (ECG), scoring of Sexual Function Questionnaire (SFQ), concomitant medication assessment, IP dispensing. • Visit 1 (Month 1 (M1) - D30 ± 3): Following items will be recorded: treatment compliance, vital signs, blood chemistry, ECG, adverse events (AEs), concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 2 (Month 2 (M2) - D60 ± 3): Following items will be recorded: treatment compliance, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. • Visit 3 (Month 3 (M3) - D90 ± 3): Following items will be recorded: vital signs, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level), concomitant medication, SFQ score, AE assessment, collecting of dispensed IP at the last visit and dispensing of new IP doses. • Visit 4 (Month 4.5 (M4) - D135 ± 3): Following items will be recorded: treatment compliance, vital signs, AEs, concomitant medication; dispensing of new IP doses and collecting of dispensed IP at the last visit. Visit 5 (Month 6 (M6)- D180 ± 3): Following items will be recorded: treatment compliance, vital signs, prostate symptom score according to IPSS, laboratory tests (hematology, blood chemistry, electrolytes, Qmax, urinalysis, 12-lead ECG, total PSA level, free-to-total PSA ratio, TRUS; concomitant medication, SFQ score, AE assessment, collecting of the previous dispensed IPs . Follow-up Phone Call (Month 7 (M7)- D210 ± 3): To record any possible AE that may occur after discontinuation of study treatment.

03

Conditions studied

  • Prostatic Hyperplasia

Browse trials for

Keywords

  • Benign Prostatic Hyperplasia
  • dutasteride and tamsulosin
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male, age ≥ 50 years. Clinical diagnosis of benign prostate hypertrophy (BPH) . International Prostate Symptom Score (IPSS) ≥ 12 Prostate volume ≥30 ml (transrectal ultrasonography). Total serum prostate specific antigen (PSA) ≥1.5 ng/mL and ≤10 ng/mL. Free-to-total PSA ratio > 20% Maximum flow rate (Qmax) >5 mL/sec and ≤15 mL/sec and post-void residual volume of \< 150 mL Willing and able to give written and comply with study procedures throughout study Able to swallow and retain oral medication Able to express personal thought and feeling Ability to read and comprehend information on the Sexual Function Inventory

Exclusion criteria

Exclusion Criteria:

History or evidence of prostate cancer (e.g. positive or ultrasound, suspicious digital rectal examination).

Previous prostatic surgery (TURP, balloon dilatation, thermotherapy and stent replacement) or other invasive procedures to treat BPH.

History of flexible/rigid cystoscopy or other instrumentation of the urethra within past 7 days History of acute urine retention (AUR) within past 3 months. Any causes other than BPH result in urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck contracture, urethral stricture, bladder , acute or chronic prostatitis, acute or chronic urinary tract infections).

History of breast cancer or clinical finding suggestive of malignancy. Use of any 5-alpha-reductase inhibitor (e.g. Proscar®, Propecia®), drugs with antiandrogenic properties (e.g. spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents), drugs which induce gynecomastia or drugs which affect prostate volume, within past 6 months and throughout the study (other than as study medication). Do not use dutasteride within past 12 months. Do not use metronidazole for a long time.

Concurrent use of anabolic steroids (eg. Durabolin®). Use of phytotherapy (eg: Tadenan®, Permixon®, etc) for BPH within 2 weeks of screening visit and/or predicted to need phytotherapy during the study.

Use of any alpha-adrenoreceptor blockers (i.e. indoramin, prazosin, terazosin, tamsulosin, alfuzosin and doxazosin) within 2 weeks of screening visit and/or predicted to need any alpha blockers other than tamsulosin during the study.

Use of any alpha-adrenoreceptor agonists (e.g. pseudoephedrine, phenylephrine, ephedrine) or anticholinergics (e.g. oxybutynin, propantheline) or cholinergics (e.g. bethanecol chloride) within 48 hours prior to all uroflowmetry assessments.

to any alpha-/beta-adrenoreceptor blocker or 5-alpha-reductase inhibitor, or other chemically-related drugs.

Concurrent use of drugs known or thought to have an interaction with tamsulosin and dutasteride.

History of hepatic impairment or abnormal liver function tests at screening (defined , AST, and/or alkaline phosphatase >2 times the , or total >1.5 times the upper limit of normal).

History of renal insufficiency, or serum creatinine >1.5 times the upper limit of normal at screening.

History of malignancies other than basal cell carcinoma or squamous cell carcinoma of the skin within the past 5 years. Subjects with a prior malignancy who have had no evidence of disease for at least 5 years prior to screening are eligible.

Any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within past 6 months; medically uncontrollable diabetes or peptic ulcer disease History of postural hypotension, dizziness, vertigo or any signs and symptoms of orthostasis, which in judgments of investigator, could be exacerbated by tamsulosin History of unsuccessful treatment with tamsulosin or 'first dose' hypotensive episode on initiation of alpha-1-adrenoreceptor antagonist therapy.

History of unsuccessful treatment with finasteride or dutasteride. Willing to have a child during the treatment period or within 6 months thereafter Having female partner who is a pregnant woman or in child-bearing age and refuse to use condom for sexual protection Willing to donate blood during treatment period or within 6 months thereafter. History or current evidence of drug or alcohol abuse within past 12 months. History of any illness might confound the results of the study or poses additional risk to the patient.

Participation in or marketed drug trial within 30 days preceding the screening visit and/or during the study treatment

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Combodart/Duodart

    Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin

    Drug: Dutasteride/Tamsulosin

Interventions

  • DrugDutasteride/Tamsulosin

    Drug pages: Dutasteride · Tamsulosin

    0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment

    Also known as: Duodart, combodart

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs

    An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.

    Time frame: From start of study medication until follow-up (up to 7 months)

  2. Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs

    An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.

    Time frame: From start of study medication until follow-up (up to 7 months)

  3. Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points

    A 12 lead ECG was measured at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5).

    Time frame: Screening, Month 1, Month 3 and Month 6

  4. Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline

    Blood samples were collected at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5) for chemistry laboratory assessments. Clinical chemistry parameters included alanine aminotrasferase (ALT), aspartate aminotrasferase (AST), creatinine, glucose, potassium, protein, sodium and urea. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for a clinical chemistry parameter are summarized.

    Time frame: Screening, Month 1, Month 3 and Month 6

  5. Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline

    Blood samples were collected at Screening, Month 3 (Visit 3) and Month 6 (Visit 5) for hematology laboratory assessments. Hematology parameters included basophils, leukocytes, hemoglobin (HGB), eosinophils, erythrocytes (ery), ery mean Corpuscular HGB concentration, ery mean corpuscular HGB, ery distribution width, lymphocytes, hematocrit, monocytes, neutrophils and platelets. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for hematology parameters are summarized.

    Time frame: Screening, Month 3 and Month 6

  6. Number Participants With a Negative or Positive Response at the Indicated Time Points

    Urine samples were collected at Screening (SC), Month 3 (3M) and Month 6 (6M) for urinalysis laboratory assesment. Final value (FV) is defined as the latest post-Baseline value available in the study for each parameter.Urinalysis parameters included erythrocytes, glucose, ketones, leukocytes and protein. Number of participants with a negative (NEG) or positive (POS) response at the indicated time points are summarized.

    Time frame: Screening, Month 3 and Month 6

  7. Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points

    Serum sample was collected at Baseline, Month 3 and Month 6 for assesment of total PSA. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Change from Baseline in total PSA at Month 3 and Month 6 was calculated as value at specified visist minus Baseline value.

    Time frame: Baseline, Month 3 and Month 6

  8. Free to Total PSA Ratio at the Indicated Time Points

    Serum sample was collected at Screening (Baseline for participants with Free to Total PSA ratio at Month 6), and Month 6 for assessment of free to total PSA ratio. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Free to total PSA ratio at Baseline for participants with free to total PSA Ratio at Month 6 and free to total PSA ratio at month 6 are presented.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6

    The IPSS is a screening tool used to assess the symptoms of prostate related disease. The IPSS questionnaire consists of seven symptoms questions including feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 (no symptoms to almost always symptoms) for a total of maximum 35 points. IPSS total is the sum of the scores of seven questions; therefore, the possible total score ranges from 0 to 35 (0-7: Mildly symptomatic; 8-19: Moderately symptomatic; 20-35: Severely symptomatic). IPSS was assessed at Baseline and Month 6. Change from Baseline was calculated as Month 6 IPSS score- minus Baseline IPSS score.

    Time frame: Baseline and Month 6

  2. Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points

    The Qmax is used as an indicator for the diagnosis of enlarged prostate. A lower Qmax may indicate that the enlarged prostate. Qmax was assessed at Baseline (screening), Month 3 and Month 6. Change from Baseline was calculated as Qmax score at specified timepoint minus the Baseline Qmax score.

    Time frame: Baseline, Month 3 and Month 6

07

Results

Posted Dec 17, 2015

Participant flow

Participant flow — Overall Study
MilestoneDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Started59
Completed52
Not completed7
Withdrew: Lost to follow-up1
Withdrew: Adverse event3
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryNumber of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs

An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.

Time frame:
From start of study medication until follow-up (up to 7 months)
Reported as:
Number · Participants
Number of Participants With Any On-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
ParticipantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Any AE13
Any SAE1
Any treatment-related AE3
PrimaryNumber of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs

An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product at any dose, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, and is associated with liver injury and impaired liver function.

Time frame:
From start of study medication until follow-up (up to 7 months)
Reported as:
Number · Participants
Number of Participants With Any Post-treatment Adverse Events (AEs) or Any Serious Adverse Event (SAEs) and Treatment-related AEs
ParticipantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Any AE2
Any SAE1
Any treatment-related AE1
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points

A 12 lead ECG was measured at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5).

Time frame:
Screening, Month 1, Month 3 and Month 6
Reported as:
Number · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings at the Indicated Time Points
ParticipantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Screening, n=5949
Month 1, n=5647
Month 3, n=5350
Month 6, n=5244
PrimaryNumber of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline

Blood samples were collected at Screening, Month 1 (Visit 1), Month 3 (Visit 3) and Month 6 (Visit 5) for chemistry laboratory assessments. Clinical chemistry parameters included alanine aminotrasferase (ALT), aspartate aminotrasferase (AST), creatinine, glucose, potassium, protein, sodium and urea. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for a clinical chemistry parameter are summarized.

Time frame:
Screening, Month 1, Month 3 and Month 6
Reported as:
Number · Participants
Number of Participants With Clinical Chemistry Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
ParticipantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
ALT, n=489
AST, n=496
Creatinine, n=519
Glucose, n=478
Potassium, n=521
Protein, n=564
Sodium, n=530
Urea, n=547
PrimaryNumber of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline

Blood samples were collected at Screening, Month 3 (Visit 3) and Month 6 (Visit 5) for hematology laboratory assessments. Hematology parameters included basophils, leukocytes, hemoglobin (HGB), eosinophils, erythrocytes (ery), ery mean Corpuscular HGB concentration, ery mean corpuscular HGB, ery distribution width, lymphocytes, hematocrit, monocytes, neutrophils and platelets. The number of participants with a shift from normal at Baseline to abnormal at any time post-Baseline for hematology parameters are summarized.

Time frame:
Screening, Month 3 and Month 6
Reported as:
Number · Participants
Number of Participants With Hematology Values Shift From Normal at Baseline to Abnormal at Any Time Post-Baseline
ParticipantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Basophils/Leukocytes, n=540
Eosinophils/Leukocytes, n=465
Ery Mean Corpuscular HGB Concentration, n=4422
Ery Mean Corpuscular Hemoglobin, n=366
Ery Mean Corpuscular Volume, n=424
Erythrocytes, n=493
Erythrocytes Distribution Width, n=43
Hematocrit, n=487
Hemoglobin, n=492
Leukocytes, n=477
Lymphocytes/Leukocytes, n=531
Monocytes/Leukocytes, n=521
Neutrophils/Leukocytes, n=415
Platelets, n=531
PrimaryNumber Participants With a Negative or Positive Response at the Indicated Time Points

Urine samples were collected at Screening (SC), Month 3 (3M) and Month 6 (6M) for urinalysis laboratory assesment. Final value (FV) is defined as the latest post-Baseline value available in the study for each parameter.Urinalysis parameters included erythrocytes, glucose, ketones, leukocytes and protein. Number of participants with a negative (NEG) or positive (POS) response at the indicated time points are summarized.

Time frame:
Screening, Month 3 and Month 6
Reported as:
Number · Participants
Number Participants With a Negative or Positive Response at the Indicated Time Points
ParticipantsDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Erythrocytes, SC, POS, n=594
Erythrocytes, SC, NEG, n=5955
Erythrocytes, 3M, POS, n=546
Erythrocytes, 3M, NEG, n=5448
Erythrocytes, 6M, POS, n=526
Erythrocytes, 6M, NEG, n=5246
Erythrocytes, FV, POS, n=547
Erythrocytes, FV, NEG, n=5447
Glucose, SC, POS, n=593
Glucose, SC, NEG, n=5956
Glucose, 3M, POS, n=541
Glucose, 3M, NEG, n=5453
Glucose, 6M, POS, n=520
Glucose, 6M, NEG, n=5252
Glucose, FV, POS, n=540
Glucose, FV, NEG, n=5454
Ketones, SC, POS, n=590
Ketones, SC, NEG, n=5959
Ketones, 3M, POS, n=542
Ketones, 3M, NEG, n=5452
Ketones, 6M, POS, n=521
Ketones, 6M, NEG, n=5251
Ketones, FV, POS, n=541
Ketones, FV, NEG, n=5453
Leukocytes, SC, POS, n=593
Leukocytes, SC, NEG, n=5956
Leukocytes, 3M, POS, n=540
Leukocytes, 3M, NEG, n=5454
Leukocytes, 6M, POS, n=526
Leukocytes, 6M, NEG, n=5246
Leukocytes, FV, POS, n=546
Leukocytes, FV, NEG, n=5448
Protein, SC, POS, n=599
Protein, SC, NEG, n=5950
Protein, 3M, POS, n=546
Protein, 3M, NEG, n=5448
Protein, 6M, POS, n=527
Protein, 6M, NEG, N=5245
Protein, FV, POS, n=548
Protein, FV, NEG, n=5446
PrimaryChange From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points

Serum sample was collected at Baseline, Month 3 and Month 6 for assesment of total PSA. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Change from Baseline in total PSA at Month 3 and Month 6 was calculated as value at specified visist minus Baseline value.

Time frame:
Baseline, Month 3 and Month 6
Reported as:
Mean · Microgram per liter (ug/L)
Change From Baseline in Total Prostate -Specific Antigen (PSA) at the Indicated Time Points
Microgram per liter (ug/L)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Month 3, n=54-1.499 ± 1.2263
Month 6, n=52-1.824 ± 1.2413
PrimaryFree to Total PSA Ratio at the Indicated Time Points

Serum sample was collected at Screening (Baseline for participants with Free to Total PSA ratio at Month 6), and Month 6 for assessment of free to total PSA ratio. PSA is a substance produced by prostate gland, and the elevated level of PSA indicates prostate cancer or any other non-cancerous condition related to prostate. Free to total PSA ratio at Baseline for participants with free to total PSA Ratio at Month 6 and free to total PSA ratio at month 6 are presented.

Time frame:
Baseline, Month 6
Reported as:
Mean · Ratio
Free to Total PSA Ratio at the Indicated Time Points
RatioDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Baseline, n=5028.207 ± 10.5868
Month 6, n=5224.887 ± 8.1112
SecondaryChange From Baseline in the International Prostate Symptom Score (IPSS) at Month 6

The IPSS is a screening tool used to assess the symptoms of prostate related disease. The IPSS questionnaire consists of seven symptoms questions including feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 (no symptoms to almost always symptoms) for a total of maximum 35 points. IPSS total is the sum of the scores of seven questions; therefore, the possible total score ranges from 0 to 35 (0-7: Mildly symptomatic; 8-19: Moderately symptomatic; 20-35: Severely symptomatic). IPSS was assessed at Baseline and Month 6. Change from Baseline was calculated as Month 6 IPSS score- minus Baseline IPSS score.

Time frame:
Baseline and Month 6
Reported as:
Mean · Scores on a scale
Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6
Scores on a scaleDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 6-8.3 ± 3.92
Statistical analysis
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points

The Qmax is used as an indicator for the diagnosis of enlarged prostate. A lower Qmax may indicate that the enlarged prostate. Qmax was assessed at Baseline (screening), Month 3 and Month 6. Change from Baseline was calculated as Qmax score at specified timepoint minus the Baseline Qmax score.

Time frame:
Baseline, Month 3 and Month 6
Reported as:
Mean · Mililiter/seconds
Change From Baseline in Maximum Rate of Urinary Flow (Qmax) at the Indicated Time Points
Mililiter/secondsDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Month 3, n=542.77 ± 4.361
Month 6, n=522.01 ± 3.684
Statistical analysis
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg · t-test, 2 sided · p = <0.001 (for Month 3)
  • Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg · t-test, 2 sided · p = <0.001 (for Month 6)

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to Month 7).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg—1/59 (1.7%)0/59 (0%)
Most frequent serious events
Most frequent serious events
EventDutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Hepatic Enzyme IncreasedInvestigations1/59

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Mean66.5 ± 8.37
Sex: Female, Male
Sex: Female, Male(Participants)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Female0
Male59
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg
Asian59
08

Study locations

1 site
  • GSK Investigational Site
    Ho Chi Minh, Vietnam
09

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2012 to primary completion in Mar 2015, 32 months.

Results were first posted in Dec 2015, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2012
First posted
Aug 28, 2012
StartActual
Jun 29, 2012
Primary completionActual
Mar 20, 2015
CompletionActual
Mar 20, 2015
Results first posted
Dec 17, 2015
Last update
Aug 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01673490
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 28, 2012
Start date
Jun 29, 2012
Primary completion
Mar 20, 2015
Completion
Mar 20, 2015
Results posted
Dec 17, 2015
Last update
Aug 20, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dutasteride · Tamsulosin

Start the discussion